retatrutide type 2 diabetes phase 2 trial 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Retatrutide is investigational and is

Inflammatory markers improved

Despite the limitations, these data suggest that long term therapy is not associated with durable weight loss with withdrawal of the medication and supports guidelines for extended therapy

Clinical trials showed modest results, and AOD-9604 was not pursued through full FDA drug approval

Learn about Retatrutide (GGG tri-agonist) medication Retatrutide is an up and coming medication, still in clinical trials and does not yet have a known time when it will be approved for use or available to the general public

Mochi leans on one-on-one video visits with providers and dietitians

The researchers concluded that most of these hormonal changes (particularly TSH and free T3) appeared to be independent of weight loss, suggesting a possible direct effect of semaglutide on thyroid regulation that still needs to be clarified, while changes in free T4 were more closely related to weight change